NBIX - Neurocrine Biosciences Inc Stock Price, Fair Value and News

134.02USD+1.03 (+0.77%)Delayed as of 17 Apr 2024, 02:55 pm ET

Market Summary

USD134.02+1.03

Delayedas of 17 Apr 2024, 02:55 pm

0.77%

NBIX Alerts

4 major insider sales recently.

NBIX Stock Price

View Fullscreen

NBIX RSI Chart

NBIX Valuation

Market Cap

13.2B

Price/Earnings (Trailing)

Price/Sales (Trailing)

7.01

EV/EBITDA

36.62

Price/Free Cashflow

36.6

NBIX Price/Sales (Trailing)

NBIX Profitability

Operating Margin

99.24%

EBT Margin

17.60%

Return on Equity

11.19%

Return on Assets

7.68%

Free Cashflow Yield

2.73%

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

1.9B

Rev. Growth (Yr)

25.05%

Rev. Growth (Qtr)

3.29%

NBIX Earnings

Earnings (TTM)

249.7M

Earnings Growth (Yr)

65.96%

Earnings Growth (Qtr)

77.74%

Breaking Down NBIX Revenue

52 Week Range

89.04134.44

(Low)(High)

Last 7 days

-4.3%

Last 30 days

-4.4%

Last 90 days

-3.0%

Trailing 12 Months

27.7%

How does NBIX drawdown profile look like?

NBIX Financial Health

Current Ratio

2.45

Debt/Equity

0.08

Debt/Cashflow

2.3

NBIX Investor Care

Shares Dilution (1Y)

3.02%

Diluted EPS (TTM)

2.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.6B	1.7B	1.8B	1.9B
2022	1.2B	1.3B	1.4B	1.5B
2021	1.0B	1.0B	1.1B	1.1B
2020	886.8M	1.0B	1.0B	1.0B
2019	518.6M	605.1M	675.5M	788.1M
2018	232.7M	323.3M	414.3M	451.2M
2017	0	6.3M	67.1M	161.6M
2016	15.0M	15.0M	15.0M	15.0M
2015	22.0M	21.2M	20.5M	19.8M
2013	40.6M	28.0M	15.5M	2.9M
2012	76.2M	74.6M	42.3M	53.1M
2011	45.3M	52.8M	80.0M	77.4M
2010	0	13.1M	23.3M	33.5M
2009	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Neurocrine Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	delaet ingrid	sold	-37,345	137	-272	chief regulatory officer
Apr 01, 2024	delaet ingrid	acquired	21,493	79.02	272	chief regulatory officer
Mar 21, 2024	delaet ingrid	acquired	517,600	103	5,000	chief regulatory officer
Mar 21, 2024	delaet ingrid	sold	-725,320	145	-5,000	chief regulatory officer
Mar 14, 2024	morrow george j	sold	-5,576,710	139	-40,000	-
Mar 14, 2024	morrow george j	acquired	795,800	39.79	20,000	-
Mar 14, 2024	benevich eric	acquired	6,067,630	80.9017	75,000	chief commercial officer
Mar 14, 2024	benevich eric	sold	-10,453,400	139	-75,000	chief commercial officer
Mar 13, 2024	delaet ingrid	sold	-420,419	140	-3,000	chief regulatory officer
Mar 13, 2024	pops richard f	acquired	992,032	42.76	23,200	-

Which funds bought or sold NBIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-20.51	-159,564	790,557	0.02%
Apr 15, 2024	THOMPSON INVESTMENT MANAGEMENT, INC.	reduced	-0.97	37,088	1,051,640	0.16%
Apr 15, 2024	Sunbelt Securities, Inc.	reduced	-10.15	-2,549	40,273	-%
Apr 15, 2024	Pallas Capital Advisors LLC	new	-	338,042	338,042	0.01%
Apr 15, 2024	Portman Square Capital LLP	unchanged	-	10,207	228,533	0.01%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	added	48.53	233,451	654,292	-%
Apr 15, 2024	NorthCrest Asset Manangement, LLC	reduced	-5.01	-4,030	706,288	0.02%
Apr 15, 2024	Concurrent Investment Advisors, LLC	new	-	331,904	331,904	0.02%
Apr 12, 2024	FCF Advisors LLC	sold off	-100	-1,157,250	-	-%
Apr 12, 2024	WASHINGTON CAPITAL MANAGEMENT, INC	reduced	-15.79	-74,180	551,680	0.45%

Are Funds Buying or Selling NBIX?

Are funds buying NBIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NBIX

No. of Funds

NBIX Alerts

4 major insider sales recently.

Unveiling Neurocrine Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.88%	9,710,328	SC 13G/A
Jan 23, 2024	blackrock inc.	13.9%	13,647,679	SC 13G/A
Feb 09, 2023	janus henderson group plc	2.5%	2,415,638	SC 13G/A
Feb 09, 2023	vanguard group inc	9.72%	9,340,295	SC 13G/A
Jan 23, 2023	blackrock inc.	13.1%	12,627,403	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	4.5%	4,359,645	SC 13G/A
Feb 10, 2022	vanguard group inc	9.26%	8,787,991	SC 13G/A
Feb 10, 2022	janus henderson group plc	7.8%	7,445,839	SC 13G/A
Jan 27, 2022	blackrock inc.	12.1%	11,476,545	SC 13G/A
Jan 26, 2022	blackrock inc.	12.1%	11,476,545	SC 13G/A

Recent SEC filings of Neurocrine Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 21, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading

Peers (Alternatives to Neurocrine Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	348.0B	85.2B	-8.67%	-12.80%	9.9	4.09	6.46%	95.94%
MRK	316.7B	60.1B	2.91%	8.74%	867.76	5.27	1.40%	-97.49%
PFE	145.1B	46.5B	-8.05%	-37.62%	-104.48	3.12	42.59%	-114.62%
AMGN	142.4B	28.2B	-1.17%	7.12%	21.2	5.05	7.09%	2.52%
GILD	83.9B	27.1B	-8.64%	-19.50%	14.81	3.09	-0.60%	23.36%
TEVA	14.7B	15.8B	-2.46%	54.12%	-25.47	0.93	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-1.38%	-18.66%	-319.58	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-17.22%	-19.16%	11.18	2.39	49.61%	324.78%
BHC	3.2B	8.8B	-5.00%	14.25%	-5.39	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-4.97%	-2.50%	14.31	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	6.36%	-26.40%	-4.05	1.92	24.65%	80.36%
TXMD	22.1M	1.3M	-20.00%	-47.68%	-2.15	0.38	-98.14%	-109.18%
ACRX	17.3M	-	-11.30%	34.21%	-0.94	0.22	2882.68%	-138.52%
AGRX	1.2M	19.6M	-27.78%	-94.56%	-0.08	0.06	80.00%	43.08%
ACOR	496.8K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Neurocrine Biosciences Inc News

Latest updates

Neurocrine Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.3%	515	499	453	420	412	388	378	311	312	296	289	237	248	259	302	237	244	222	184	138	131
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	-	1.00	-
Costs and Expenses	2.0%	365	358	379	535	309	300	324	308	348	252	226	205	176	303	226	178	-	132	149	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	326	-	-	-	176	303	226	178	195	132	149	239	110
S&GA Expenses	7.2%	219	204	222	243	183	186	183	201	157	155	143	129	107	113	97.00	118	101	85.00	81.00	88.00	69.00
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	73.00	-	-	-	58.00	-	-	62.00	38.00	39.00
EBITDA Margin	22.7%	0.19*	0.15*	0.15*	0.07*	0.16*	0.08*	0.04*	0.11*	0.12*	0.18*	0.10*	0.13*	-	-	-	-	-	-	-	-	-
Interest Expenses	0%	1.00	1.00	1.00	1.00	1.00	1.00	2.00	3.00	7.00	7.00	6.00	6.00	8.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Income Taxes	55.4%	51.00	33.00	26.00	-26.70	29.00	29.00	-6.40	8.00	-6.50	8.00	15.00	-4.90	-306	1.00	4.00	2.00	5.00	5.00	1.00	-0.50	-
Earnings Before Taxes	71.5%	198	116	122	-103	118	98.00	-23.30	21.00	-13.80	31.00	58.00	27.00	42.00	-57.10	83.00	39.00	39.00	58.00	52.00	-102	19.00
EBT Margin	24.7%	0.18*	0.14*	0.14*	0.06*	0.14*	0.06*	0.01*	0.08*	0.09*	0.15*	0.07*	0.09*	-	-	-	-	-	-	-	-	-
Net Income	77.7%	148	83.00	96.00	-76.60	89.00	69.00	-16.90	14.00	-7.30	23.00	42.00	32.00	348	-57.60	80.00	37.00	34.00	54.00	51.00	-102	18.00
Net Income Margin	23.6%	0.13*	0.11*	0.11*	0.04*	0.10*	0.04*	0.01*	0.06*	0.08*	0.42*	0.35*	0.38*	-	-	-	-	-	-	-	-	-
Free Cashflow	-42.2%	118	204	173	-133	141	101	129	-48.10	-4.70	56.00	99.00	83.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	14.2%	3,251	2,848	2,613	2,360	2,369	2,143	2,006	2,145	2,073	2,017	1,956	1,846	1,735	1,503	1,516	1,362	1,306	1,180	1,067	958	993
Current Assets	-2.6%	1,607	1,650	1,497	1,433	1,454	1,206	1,019	1,018	973	1,006	1,110	1,085	1,016	1,157	1,146	968	831	819	749	633	738
Cash Equivalents	-14.5%	251	294	160	104	263	212	163	270	344	311	368	353	190	425	415	187	116	172	147	78.00	147
Inventory	33.0%	38.00	29.00	32.00	33.00	35.00	37.00	29.00	29.00	31.00	26.00	28.00	30.00	28.00	21.00	22.00	21.00	17.00	11.00	12.00	13.00	11.00
Net PPE	2.9%	71.00	69.00	66.00	63.00	59.00	61.00	67.00	64.00	59.00	51.00	50.00	45.00	45.00	43.00	45.00	42.00	42.00	40.00	40.00	37.00	34.00
Liabilities	20.5%	1,019	846	760	675	661	599	582	753	699	671	677	641	609	698	684	662	669	605	583	548	512
Current Liabilities	-5.3%	655	692	583	374	538	485	286	254	246	226	213	190	187	611	573	140	565	116	101	72.00	88.00
Long Term Debt	-	-	-	-	170	-	-	169	378	335	331	326	322	318	-	-	414	-	404	398	393	388
LT Debt, Current	0.1%	170	170	170	-	169	169	-	-	-	-	-	-	-	425	420	-	409	-	-	-	-
LT Debt, Non Current	-	-	-	-	170	-	-	169	378	335	331	326	322	318	-	-	414	-	404	398	393	388
Shareholder's Equity	11.5%	2,232	2,002	1,853	1,685	1,708	1,545	1,423	1,391	1,374	1,346	1,279	1,206	1,126	804	831	700	637	575	484	409	481
Retained Earnings	48.5%	-157	-304	-387	-483	-406	-495	-564	-547	-635	-628	-651	-693	-725	-1,073	-1,015	-1,095	-1,132	-1,166	-1,220	-1,271	-1,177
Additional Paid-In Capital	3.2%	2,382	2,309	2,242	2,171	2,122	2,054	2,000	1,948	2,011	1,974	1,929	1,898	1,850	1,874	1,842	1,797	1,768	1,740	1,703	1,681	1,660
Shares Outstanding	0.5%	99.00	98.00	98.00	98.00	97.00	96.00	95.00	95.00	95.00	95.00	94.00	94.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	7,900	-	-	-	8,097	-	-	-	9,105	-	-	-	11,232	-	-	-	5,753	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-41.7%	123,500	212,000	179,600	-125,200	143,000	98,800	138,100	-40,500	4,200	61,800	103,200	87,300	94,500	-20,400	118,900	35,500	97,500	97,800	64,200	-112,500	50,490
Share Based Compensation	-20.3%	38,100	47,800	68,500	39,900	43,500	43,100	49,500	37,000	35,600	37,100	28,600	32,900	21,000	26,700	29,500	22,800	21,300	20,300	17,900	15,800	13,300
Cashflow From Investing	-107.4%	-201,800	-97,300	-125,900	-42,100	-115,600	-61,300	31,400	-31,600	23,700	-126,200	-90,800	63,100	-147,700	25,200	93,400	33,200	-166,200	-85,600	-300	41,000	-106,241
Cashflow From Financing	88.3%	35,400	18,800	2,900	8,200	24,600	11,400	-276,400	6,100	1,800	7,500	3,000	15,100	-185,000	5,400	15,800	6,000	12,400	13,100	4,300	2,600	1,752

NBIX Income Statement

2023-12-31

Consolidated Statements Income and Comprehensive Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenues	$ 1,887.1	$ 1,488.7	$ 1,133.5
Operating expenses:
Cost of revenues	39.7	23.2	14.3
Research and development	565.0	463.8	328.1
Acquired in-process research and development	143.9	0.0	105.3
Selling, general and administrative	887.6	752.7	583.3
Total operating expenses	1,636.2	1,239.7	1,031.0
Operating income	250.9	249.0	102.5
Other income (expense):
Interest expense	(4.6)	(7.1)	(25.8)
Unrealized gain on equity securities	28.4	30.8	20.9
Loss on extinguishment of convertible senior notes	0.0	(70.0)	0.0
Investment income and other, net	57.4	11.2	3.8
Total other income (expense), net	81.2	(35.1)	(1.1)
Income before provision for income taxes	332.1	213.9	101.4
Provision for income taxes	82.4	59.4	11.8
Net income	249.7	154.5	89.6
Foreign currency translation adjustments, net of tax	2.4	2.9	0.0
Unrealized gain (loss) on debt securities available-for-sale, net of tax	12.5	(9.1)	(3.5)
Comprehensive income	$ 264.6	$ 148.3	$ 86.1
Earnings per share, basic (in USD per share)	$ 2.56	$ 1.61	$ 0.95
Earnings per share, diluted (in USD per share)	$ 2.47	$ 1.56	$ 0.92
Weighted average common shares outstanding, basic (in shares)	97.7	95.8	94.6
Weighted average common shares outstanding, diluted (in shares)	101.0	98.9	97.9
Net product sales
Revenues:
Revenues	$ 1,860.6	$ 1,440.9	$ 1,090.1
Collaboration revenue
Revenues:
Revenues	$ 26.5	$ 47.8	$ 43.4

NBIX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 251.1	$ 262.9
Debt securities available-for-sale	780.5	726.4
Accounts receivable, net	439.3	350.0
Inventory, net	38.3	35.1
Other current assets	97.8	79.1
Total current assets	1,607.0	1,453.5
Deferred tax assets	362.6	305.9
Debt securities available-for-sale	687.5	299.4
Right-of-use assets	276.5	87.0
Equity securities	161.9	102.1
Property and equipment, net	70.8	58.6
Intangible assets, net	35.5	37.2
Other assets	49.6	25.0
Total assets	3,251.4	2,368.7
Current liabilities:
Accounts payable and accrued liabilities	448.8	347.6
Convertible senior notes	170.1	169.4
Other current liabilities	35.9	20.7
Total current liabilities	654.8	537.7
Noncurrent operating lease liabilities	258.3	93.5
Other long-term liabilities	106.3	29.7
Total liabilities	1,019.4	660.9
Stockholders’ equity:
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding	0.0	0.0
Common stock, $0.001 par value; 220.0 shares authorized; 98.7 and 96.5 shares issued and outstanding, respectively	0.1	0.1
Additional paid-in capital	2,382.0	2,122.4
Accumulated other comprehensive income (loss)	7.0	(7.9)
Accumulated deficit	(157.1)	(406.8)
Total stockholders’ equity	2,232.0	1,707.8
Total liabilities and stockholders’ equity	$ 3,251.4	$ 2,368.7

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Ã‚â€“ Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

CEO	Dr. Kevin C. Gorman Ph.D.
WEBSITE	neurocrine.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1350

Neurocrine Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

As of Tue Apr 16 2024, market cap of Neurocrine Biosciences Inc is 13.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers. The fair value of Neurocrine Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neurocrine Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neurocrine Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, NBIX's PE ratio (Price to Earnings) is 53 and Price to Sales (PS) ratio is 7.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Neurocrine Biosciences Inc's stock?

In the past 10 years, Neurocrine Biosciences Inc has provided 0.258 (multiply by 100 for percentage) rate of return.